Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genmab, in collaboration with Seagen and other partners, is conducting a clinical study titled ‘A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer.’ The study aims to evaluate the safety and efficacy of Tisotumab Vedotin, both as a standalone treatment and in combination with other cancer agents, for patients with advanced cervical cancer. This research is significant as it seeks to provide new therapeutic options for a challenging stage of cervical cancer.
The study tests Tisotumab Vedotin, an investigational drug administered intravenously, alone and in combination with Bevacizumab, Pembrolizumab, and Carboplatin. These combinations aim to enhance treatment efficacy for patients with recurrent or advanced cervical cancer.
This interventional study is non-randomized with a parallel assignment model and no masking, focusing primarily on treatment. It includes a dose escalation phase to determine the optimal dosage, followed by an expansion phase to further assess efficacy and safety.
The study began on February 27, 2019, with the primary completion date yet to be reached. The last update was submitted on July 10, 2025, indicating ongoing progress and adjustments in the study’s timeline.
The outcome of this study could significantly impact Genmab’s market position and investor sentiment, especially if the results show positive efficacy and safety profiles. This could also influence the competitive landscape in oncology, particularly for companies developing treatments for cervical cancer.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.